Apeiron Biologics is headquartered in Vienna, Austria.
Apeiron Biologics has 35 employees.
Apeiron Biologics is a life science company.
Apeiron Biologics was founded in 2006.
Campus-Vienna-Biocenter 5,
Vienna,
1030
Austria,
+43 (0) 1 86565 77
www.apeiron-biologics.com
Apeiron Biologics is a private biopharmaceutical company that co-developed QARZIBA (dinutuximab beta), a high-risk neuroblastoma drug, which it licensed to EUSA Pharma (UK) Limited (now a Recordati S.p.A. company) in 2016. The company also maintains a portfolio of more than 400 patents including the intellectual property and licenses for an early-stage immuno-oncology portfolio currently being developed by invIOs Holding AG which was spun-off from APEIRON in 2022. Apeiron Biologics was formed in 2000 and is based in
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.0/yr) | # | - | - | - | - | - | - | 0 |
| Sell (0.0/yr) | # | 1 | - | - | - | - | - | 1 |
| 1 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
